Re:Insulin is way too expensive. California has a solution: ...
by RcouF1uZ4gsC on Thursday February 09, 2023 @02:59PM
(#34730416)
>. For a generic insulin to get FDA approval it needs bioequivalence which is a lot like running the original safety and effect studies over again
That is incorrect. A bioequivalence study is much simpler and cheaper than the original safety and efficacy studies.
You do not need to prove that safety and efficacy of the drug, only that you are delivering the equivalent of the originally studied drug at the same doses.
Re:Insulin is way too expensive. California has a solution: ...
by peyton on Thursday February 09, 2023 @03:17PM
(#34730722)
No, the submission packages for anything chronically administered (like insulin follow-on) are way more comprehensive.
Re:Insulin is way too expensive. California has a solution: ...
by projektfu on Thursday February 09, 2023 @04:38PM
(#34731904)
Thank you. Insulin, being a biological, can't prove equivalence through just equivalent pharmacokinetics and contents.
Re:Insulin is way too expensive. California has a solution: ...
by basch on Thursday February 09, 2023 @04:39PM
(#34731919)
>insulin glargine, are off patent now.
In the U.S.A. is expected to expire on 2027-07-05.
How did something invented in 2000, get patented in 2009? https://patents.google.com/patent/US8048854B2/en%3C/
Re:Insulin is way too expensive. California has a solution: ...
by projektfu on Thursday February 09, 2023 @10:06PM
(#34735143)
That's a different molecule. It's been animated.
California, on the other hand, is paying a lot of money to Novo Nordisk et al, and would benefit from reaching a low average price. They can afford to go through the approval process with all the important insulin analogs. And they won't go bankrupt in court before it pays off.